Close
ACHEMA MIDDLE EAST 2026

Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

For the first time in the week starting May 16th, Japan's three major pharmaceutical trade associations joined forces to call for changes to the...

Diabetes Drug By Eli Lilly Has Been Approved By The FDA

With high hopes, Eli Lilly's Mounjaro (tirzepatide) was promoted to the big leagues in the week ending May 14, when the FDA approved the...

mRNA Booster Investment Can Be A Smart Move In Poor Nations

Because of their inexpensive cost, vaccinations made with inactivated SARS-CoV-2 viruses are widely used in underdeveloped countries. As per new research from Sweden's Karolinska...

Pfizer Buys Biohaven For $11.6 Billion Betting On CGRP Meds

Pfizer is putting its substantial gain from COVID-19 drugs to good use by making deals. The company has decided it wants more, six months...

Early COVID-19 Cases Still Suffering Lingering Symptoms

As per a new study that may be one of the oldest and largest on record to track people with protracted COVID, the vast...

Boosters For COVID-19 Considerably Vital Than In The Past

The Biden administration estimates that up to 100 million additional individuals could contract COVID-19 in the fall and winter due to diminishing immunity and...

In DELIVER Phase III Study, Farxiga Achieved Primary Outcome

DELIVER is the world's largest study of heart failure with intact ejection fraction. The DELIVER phase 3 trial produced favourable findings for AstraZeneca. It...

Subscribe Our Newsletter

White Papers

The Future of Digital Health

The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...